Eleven Researchers Honored With Conquer Cancer Merit Awards

Merit Award Emblem

The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) is pleased to announce the recipients of the Genitourinary Cancers Merit Awards. Conquer Cancer Merit Awards recognize oncology fellows’ and trainees’ high-quality research submitted in abstracts to an ASCO-sponsored or cosponsored meeting, and the selected early-career researchers of the Genitourinary Cancers Merit Awards will present their findings at the 2019 Genitourinary Cancers Symposium in San Francisco, Calif.

The following individuals are 2019 Genitourinary Cancers Symposium Merit Award recipients:

  • Jad Chahoud, MDUniversity of Texas MD Anderson Cancer Center

Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors. (Abstract 505)

  • Manon de Vries-Brilland, MScIntegrated Centers of Oncology (ICO) Paul Papin, Angers, France

Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study. (Abstract 582)

  • Shaan Dudani, MBChBTom Baker Cancer Centre, University of Calgary

First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (Abstract 584)

  • Stefanie Christine Fischer, MDUniversity of Manchester, and The Christie Manchester

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma. (Abstract 510)

  • Yesser Ged, MBBS, MRCPMemorial Sloan Kettering Cancer Center

Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts). (Abstract 551)

  • Melissa J. Huynh, MDBrigham and Women's Hospital

Associations of cell cycle genetic variants with aggressive prostate cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. (Abstract 175)

  • Jean-Michel Lavoie, MDBC Cancer

Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC). (Abstract 509)

  • Rebeca Lozano Mejorada, MDSpanish National Cancer Research Centre

Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study. (Abstract 264)

  • Tim Nestler, MD, University Hospital of Cologne

Seminomatous germ cell tumors are heterogenic and metastasis can be predicted based on a gene signature of the tumor invasive front. (Abstract 528)

  • Adam Sharp, MD, PhDThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue. (Abstract 151)

  • Yee Pei Song, MRCP, FRCRThe University of Manchester

Long-term outcomes of hypoxia modification in bladder preservation: Update from BCON trial. (Abstract 356)

The 2019 Conquer Cancer Foundation of ASCO Merit Awards in genitourinary cancers are supported by Agios Pharmaceuticals, Inc.; ASCO Employees; AstraZeneca; Friends and Family of Dr. and Mrs. Ronald Beller; Dr. and Mrs. Douglas W. Blayney; Breast Cancer Research Foundation®; Bristol-Myers Squibb; Jonathan K. and Cora Y. Cho Charitable Fund; Eisai Inc.; Estate of Darla C. Ellis; G1 Therapeutics; GlaxoSmithKline Oncology; Dr. Arti Hurria and Dr. Hyman B. Muss; Ipsen Biopharmaceuticals Inc.; Dr. Michael Kelley and Dr. Elise Hoffman; Kidney Cancer Association; Lilly; Loxo Oncology; Friends and Family of Dr. James B. Nachman; Northern New England Clinical Oncology Society; Dr. Kathleen Pritchard Medicine Professional Corporation; Sarah Cannon Research Institute; Dr. Frances A. Shepherd; Dr. Stephen A. Sherwin; Drs. Rachna and Puneet Shroff; Dr. Nizar M. Tannir; TESARO; and Dr. Michael and Mrs. Deborah Troner.

For more information on the Merit Awards program or instructions on how to apply, visit CONQUER.ORG/Merit-award.